Sample Scenario — Regulatory & Compliance Failure Simulation

The Kestrel Compliance Failure Exercise

A branching, choose-your-path tabletop built for a cross-border payments fintech. Nothing was hacked and nothing went down — a control simply stopped working, and nobody noticed for nineteen months. Six shared injects establish the failure, then the room's own decision — suspend the affected services, or keep operating under manual controls — sends the exercise down one of two independent, fully-scripted paths. Both of them end in front of a regulator.

16injects per path
2diverging paths
10 dayssimulated timeline
3.5 hrstypical runtime

Fictional, but built to feel real in the room.

Every detail below is fictional — specific enough to feel real in the room, and generic enough to map onto almost any regulated firm whose license to operate depends on controls most of its leaders never see.

Kestrel Remit

A venture-backed money transmitter headquartered in Miami, licensed in 47 states, moving about $9B a year in cross-border payments for 1.3 million customers — most of them sending money to family abroad. ~650 employees. Kestrel operates through a sponsor bank, Harborline Bank, and is preparing for an IPO in six months.

Kestrel's growth story is speed and price. Its license to operate is its anti-money-laundering and sanctions program — the transaction monitoring and screening controls that regulators, its sponsor bank, and its future public shareholders all assume are working. Nobody outside compliance looks at them until they fail.

Harborline Bank — sponsor bank, carries regulatory exposure for Kestrel's flows
State regulators — 47 licenses, coordinated multistate supervision
Halden Ventures — lead investor, 22% stake, IPO in six months
Customers — 1.3M senders, six higher-risk corridors = 28% of revenue

The crisis everyone faces.

Six injects, delivered over the first 47 hours, that every player experiences regardless of what the room ultimately decides. This phase ends with the decision that splits the exercise in two.

DAY 0
10:15
INJECT 1Detection

A junior analyst's spreadsheet

A compliance analyst eight months into the job notices that alert volumes for the six higher-risk corridors dropped 70% after a platform migration nineteen months ago — and never recovered. She traces it to a rule set that was disabled during the migration and never turned back on.

Tests: whether a junior employee's finding reaches the BSA officer and the chief compliance officer the same day, or sits in an inbox.
17:00
INJECT 2Scoping

240,000 transactions nobody looked at

The BSA officer confirms it: about 240,000 transactions, totaling $410M, never ran through the structuring and high-risk corridor rules. A preliminary re-screen against sanctions lists returns 14 potential matches.

Tests: scoping a lookback while separating the urgent question — possible sanctions violations — from the large one.
DAY 1
09:00
INJECT 3Governance

The finding that was marked closed

Internal audit pulls its files. Eleven months ago, an audit flagged an "anomalous decline in alert volume" — and the former chief compliance officer marked it remediated with no supporting evidence. She left the company in the spring.

Tests: owning a governance failure that the organization's own controls caught — and then let go.
13:00
INJECT 4Whistleblower

"I already reported this"

An operations manager emails the CEO: he raised the alert-volume issue internally last year, nothing happened, and he filed a whistleblower tip with a regulator four months ago. He wants to know whether he's in trouble.

Tests: assuming the regulator may already know — and handling a protected whistleblower with no hint of retaliation.
16:00
INJECT 5Sponsor bank

The partner asks first

On a routine call, Harborline's BSA officer asks why Kestrel's suspicious activity referrals have dropped so sharply over the past year. Harborline's own regulatory exam starts next month, and Kestrel's flows are in scope.

Tests: candor with a partner whose license is exposed to your failure — before you have all the answers.
DAY 2
09:00
INJECT 6Decision point

Suspend, or keep the lights on

Outside counsel and the compliance team present two options: suspend all six higher-risk corridors until a lookback is complete — 28% of revenue, and 300,000 customers who can't send money home — or keep operating while 30 contract reviewers manually check every transaction in those corridors. Halden Ventures is asking what this does to the IPO. The room has to decide.

Tests: balancing regulatory exposure, customer harm, and business survival when every option carries all three. This is the fork.

The room decides. The exercise branches.

INJECTS 1–6 DECISION A — SUSPEND B — KEEP OPERATING

From here, the facilitator runs one of two fully independent scripts depending on what the room chose in Inject 6. Toggle between them below to see how each one unfolds — in a live session, players only ever see the one they earned.

Path A — the room suspends the corridorsTen injects. Suspending buys regulatory credibility, not forgiveness — and the people who pay first are the customers who did nothing wrong.
DAY 2
15:00
INJECT 7ACustomers

Three hundred thousand notices

Kestrel notifies 300,000 customers that transfers to six countries are paused "for a compliance review." Within hours, support queues pass 40,000 contacts. Many customers send money to cover rent, school fees, or medical care for family abroad.

Tests: customer communications about a suspension when you can't say why, or for how long.
DAY 3
10:00
INJECT 8AMedia

"Cut off without warning"

Community organizations hold a press conference about families losing access to remittances. A member of Congress sends a letter asking why customers from specific countries were cut off. The coverage frames the pause as discriminatory.

Tests: explaining a risk-based compliance decision to people who experience it as being targeted.
16:00
INJECT 9AInvestors

The IPO math changes

Halden Ventures tells the board the IPO is off the calendar for at least two quarters and asks whether management has the right compliance leadership. Two competitors are already running ads aimed at Kestrel's paused customers.

Tests: investor relations when the right compliance decision and the right business decision diverge.
DAY 4
11:00
INJECT 10ASanctions

Three confirmed matches

The re-screen confirms 3 of the 14 potential matches as true sanctions hits — payments totaling $186,000 that should have been blocked. Counsel recommends a voluntary self-disclosure to sanctions authorities, which must be made before regulators raise the issue themselves.

Tests: making a self-disclosure decision quickly enough to keep it voluntary.
DAY 5
14:00
INJECT 11ARegulatory

The exam moves up

State regulators, coordinating through a multistate process, move Kestrel's next exam up by five months and request a written lookback plan within ten business days — including who will perform it and how independence will be assured.

Tests: producing a credible remediation plan on a regulator's timeline, not your own.
DAY 6
10:00
INJECT 12ALookback

Sixteen weeks and nine million dollars

The consulting firm scoping the lookback estimates sixteen weeks and $9M. Kestrel's cash runway, with 28% of revenue paused, is about nine months.

Tests: funding remediation when its cost is now a solvency question.
DAY 7
09:00
INJECT 13ASponsor bank

Not enough

Harborline sends formal notice: suspension alone doesn't address its concerns. Unless Kestrel appoints an independent compliance monitor and gives Harborline weekly reporting, it will terminate the program agreement in 90 days.

Tests: negotiating with a partner who holds your license to operate — and whose own regulator is watching.
DAY 8
12:00
INJECT 14AAccountability

Who turned it off?

The engineering team that ran the migration and the compliance team that signed off on it are blaming each other in meetings and in writing. A trade publication quotes the former chief compliance officer saying she warned leadership about migration risk.

Tests: accountability that fixes the process without scapegoating individuals — while everything written becomes discoverable.
DAY 9
09:00
INJECT 15ADecision point

Two corridors are clean

Accelerated lookback work on two of the six corridors finds no further sanctions issues. The business wants to resume them immediately to stop the revenue bleed. Compliance says resuming before the full lookback and regulator sign-off would look like the problem was never taken seriously. The room has to decide.

Tests: whether the room can resist relief that hasn't been earned yet — and who decides when "enough" is enough.
DAY 10
11:00
INJECT 16ARemediation

A consent order is coming

Counsel advises that regulators are likely to propose a consent order with a monitor, a civil money penalty, and limits on growth. The board asks what a three-year remediation program will look like and who will run it.

Tests: separating short-term relief from the multi-year remediation that the regulators — and the business — will now require.
Path B — the room keeps operating under manual reviewTen injects. Operating protects customers and revenue, not the company — and every transaction approved from here on is one the room chose to let through.
DAY 2
16:00
INJECT 7BManual review

Nine hundred an hour

Thirty contract reviewers start manually checking every transaction in the six corridors. By evening, the queue holds 18,000 transactions and reviewers are clearing about 900 an hour, with a near-100% pass rate.

Tests: whether a compensating control is actually controlling anything — and who is checking the checkers.
DAY 3
11:00
INJECT 8BSanctions

A live hit got through

A transaction approved by a manual reviewer this morning matches a sanctioned entity. The funds have already been paid out. It's a new apparent violation — made during the remediation, under the room's decision.

Tests: responding to a fresh violation caused by the control the room chose.
17:00
INJECT 9BSponsor bank

Harborline finds out on its own

Harborline's monitoring flags the change in Kestrel's review patterns and asks what's going on. When told, its BSA officer is furious that Kestrel kept operating without telling the bank first, and demands daily reporting.

Tests: the cost of a partner learning something from its own systems instead of from you.
DAY 4
10:00
INJECT 10BRegulatory

The whistleblower's tip lands

A state regulator calls the chief compliance officer, referencing a whistleblower complaint about transaction monitoring. She asks directly: when did Kestrel learn of the problem, and why are the corridors still open?

Tests: a truthful, consistent answer to a regulator who may already know more than you've said.
DAY 5
15:00
INJECT 11BSanctions

Less voluntary now

The re-screen confirms 3 of the original 14 matches, plus the new hit from Day 3. Counsel advises that a self-disclosure will still help — but that keeping the corridors open after discovery will weigh against Kestrel when penalties are set.

Tests: self-disclosure when the strongest mitigating factors have already been spent.
DAY 6
09:00
INJECT 12BEmployees

"We were told to clear the queue"

Two compliance analysts resign. One tells HR she was pressured by an operations manager to "clear the queue" faster, and that she approved transactions she wasn't comfortable with.

Tests: culture under pressure — and whether the room treats this as an HR issue or a control failure.
DAY 7
07:00
INJECT 13BMedia

A fintech's control failure, in print

A national financial outlet reports that a "fast-growing payments startup" kept operating for days after discovering a monitoring failure, citing sources at the company and the analyst's resignation.

Tests: communications when the story isn't the original failure, but what you did after you found it.
DAY 8
16:00
INJECT 14BSponsor bank

Sixty days to find a new bank

Harborline issues a termination notice: the program agreement ends in 60 days. Without a sponsor bank, Kestrel can't move money in most states. Two prospective replacement banks decline to take a meeting.

Tests: existential risk — and whether leadership treats it as a negotiation or a business continuity event.
DAY 9
09:00
INJECT 15BDecision point

Suspend now, under duress

With Harborline leaving and regulators asking why the corridors stayed open, the room faces the decision it declined a week ago: suspend the six corridors — now as a damage-control move, not a voluntary one — or keep operating to preserve revenue while it searches for a new bank. The room has to decide.

Tests: whether the room can make the decision on its merits, or only in reaction to the consequences of the first one.
DAY 10
10:00
INJECT 16BGovernance

The board wants a different team

The IPO is withdrawn. Halden Ventures and two other directors propose replacing the CEO and chief compliance officer and bringing in an interim leader with regulatory credibility. The CEO asks the board for 30 days to stabilize the company first.

Tests: separating the immediate leadership question from the longer rebuild of trust with regulators, partners, and customers.

What the debrief surfaces.

The two paths are built to converge on the same hard questions, arrived at from opposite directions.

If the room suspended the corridors

  • Was customer harm weighed explicitly in the suspension decision — and was there a plan to communicate it before the notices went out?
  • How did a disabled control survive a migration sign-off and an audit finding — and who owns that process now?
  • What does "enough remediation" mean before restarting a service, and who has the authority to decide it?

If the room kept operating

  • Was the manual review designed to catch problems, or to clear the queue — and who was measuring its quality?
  • Why did the sponsor bank learn about the decision from its own monitoring?
  • At what point did continuing to operate become the bigger risk, and was anyone watching for it?
Kestrel Remit, Harborline Bank, Halden Ventures, and all named details in this scenario are fictional and created for exercise purposes only.

Want this as a PDF?

The full Kestrel scenario — every inject, both paths, and the debrief questions — is available as a print-ready PDF you can share with your own team or board. Enter your email and we'll take you straight to the download.

This is one scenario. Yours would be built around your business.

The Kestrel exercise is a sample — built to show how a compliance failure simulation can branch on the decision that actually matters, and stay uncomfortable in both directions. A simulation built for your organization starts with your regulators, your control environment, and your escalation paths.

Confidential by design

Exercises often require access to crisis plans, escalation structures, and vulnerabilities. That material is handled in confidence, and NDAs are available on request.

Talk to us about a custom simulation →